OmicSyn

OmicSyn is an AI-driven bio healthcare company focused on clinical medicine and multi-omics diagnostics and therapeutics. By integrating real-world clinical data with advanced AI technologies, we create innovative solutions that improve precision medicine, clinical research, and patient care.

Through collaboration with hospitals, researchers, and industry partners, OmicSyn aims to advance more predictive, personalized, and data-driven healthcare for a healthier future.

Review Our History

Background of company establishment and key R&D activities

Established the Korea Leukemia Bank supported by

Korea National Research Foundation(KRF)

south

Indicated as a representative molecular research lab by

Novartis pharma

south

Established an online database service system

for the Asia Leukemia Registry Database

south

Initiated a research on AI-based clinical management of

leukemia patients

south

Established OmicSyn Co., Ltd.

south

Patent Granted for AI Clinical Decision Support

Selected for National R&D Program by MOTIE

south

Development of HemaCDS, Bnote app as a H-Platform

south

Development of Dnote app

Selected for Multi-Ministerial Medical R&D Program